Nabi Biopharmaceuticals Professorship in Transplantation
The Nabi Biopharmaceuticals Professorship in Transplantation was funded by Nabi, a biopharmaceutical company based in Boca Raton, Fla., with a broad portfolio of products that prevent and treat infectious diseases and immune disorders. The company has worked extensively with University of Virginia researchers to explore innovative uses for the company's leading immunotherapeutic product, H-BIG, which has been used to prevent infection following exposure to the hepatitis B virus. This professorship supports a transplant pharmacologist whose research focuses on new therapies to improve the outcome of transplant procedures for patients with viral hepatitis and other immunological disorders.
The Board of Visitors elected Kenneth L. Brayman, MD, PhD, to the Nabi Biopharmaceuticals Professorship in Transplantation in 2006. Dr. Brayman serves in a leadership role at the University of Virginia where he is the chief of the transplant division in the Department of Surgery as well as the director of the transplant program for the U.Va. Health System.Dr. Brayman's clinical and research interests continue to be in line with Nabi's portfolio to prevent and treat immune disorders and improve the outcome of transplant procedures for patients with immunological disorders. He is dedicated to expanding diabetes- and transplant-related research programs at the University of Virginia, while simultaneously providing patient care, acting in leadership roles across disciplines, and serving as a mentor for students, residents, and junior faculty.In the past year, Dr. Brayman has worked to explore factors that affect clinical responses to islet transplantation and the development of new methods for assessment of islet viability following isolation and transplantation. His research focuses on increasing the islet survival post-transplant by the use of anti-inflammatory drugs, biomatrix scaffolds, and adipose-derived stem cells to precondition graft sites by inhibiting inflammation and increasing angiogenesis and neovascularization. He is also investigating the role of polyclonal serum IgM to prevent onset of autoimmune diabetes and improve islet transplantation.He participates on numerous local and national committees and serves as a reviewer for several journals. Dr. Brayman has an active presence at conferences and seminars, including attendance in the past year at the American Transplant Congress, the Southern Surgical Association Meeting, and the 2010 Annual Rachmiel Levine Diabetes and Obesity Symposium. In the coming year, his goal is to build on collaborative programs of research in transplant and diabetes, incorporating unique approaches such as the establishment of a transplant biorepository, to provide excellence in research and clinical care.